All In Biotech

Free tool

FAERS Monitor: Aklief

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 211527 or its brand name (Aklief, Trifarotene). Reports on generic versions are filed under their own applications.

Reports

183

Serious

43

23% of reports

Hospitalization

9

Death reported

2

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • erythema28
  • acne17
  • skin burning sensation17
  • urinary retention16
  • dry skin15
  • mydriasis15
  • skin exfoliation14
  • skin irritation13
  • off label use12
  • drug ineffective11
  • vision blurred10
  • pain of skin9
  • product use in unapproved indication9
  • skin hyperpigmentation9
  • intentional underdose7

Reports by year received

View as table
YearReports
20171
202026
202141
202220
202342
202421
202518
202614

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,976 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
mydriasisSignal15134.582.81,856
skin hyperpigmentationSignal9120.563.7950
intentional underdoseSignal7110.253.3652
urinary retentionSignal1655.134.5798
pain of skinSignal938.420.3292
skin irritationSignal1332.619.3368
skin burning sensationSignal1727.317.3406
acneSignal1725.816.4382
skin exfoliationSignal1419.111.5223
erythemaSignal2815.711.1373
dry skinSignal1512.98.0154
vision blurredSignal108.44.658
product use in unapproved indicationSignal94.22.219
off label use121.60.92
drug ineffective111.00.50

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.